NEW YORK (GenomeWeb) — Rosetta Genomics said today that it is collaborating with the Institute of Molecular Translational Medicine (IMTM) at Palacky University in the Czech Republic to validate and develop a new thyroid cancer diagnostic tool.

Under the agreement, Rosetta and IMTM will work toward improving the diagnosis of malignant tumors in suspected thyroid cancer patients by connecting expertise and clinical samples at IMTM with Rosetta's microRNA platform technology and product development expertise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.